Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Neuroblastoma 4Multiple Myeloma 2Vaccinia 1Transplant-Related Hematologic Malignancy 1Recurrence 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Cyclophosphamide 13Temozolomide 10Magnetic Resonance Spectroscopy 10dinutuximab 8X-Rays 8Specimen Handling 8Irinotecan 8Biopsy 8Phantoms, Imaging 7Topotecan 6Nuclear Medicine Department, Hospital 6fludarabine 5Vincristine 53-Iodobenzylguanidine 5fludarabine phosphate 4Granulocyte-Macrophage Colony-Stimulating Factor 4Etoposide 4tipifarnib 3sargramostim 3Radiotherapy 3Melphalan 3Isotretinoin 3Filgrastim 3Doxorubicin 3Carboplatin 3ulixertinib 2tazemetostat 2selpercatinib 2saponin QA-21V1 2pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neuroblastoma × Granulocyte-Macrophage Colony-Stimulating Factor × 90 days × Clear all
NCT04936529 2026-05-07

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
286 enrolled
CNS

Neuroblastoma

NCT07537400 2026-04-17

Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Shaare Zedek Medical Center

Phase 2 Not yet recruiting
10 enrolled
CNS

Neuroblastoma

NCT01857934 2026-04-16

Therapy for Children With Advanced Stage Neuroblastoma

St. Jude Children's Research Hospital

Phase 2 Completed
153 enrolled 12 charts
CNS

Neuroblastoma

NCT06450041 2026-03-23

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

New Approaches to Neuroblastoma Therapy Consortium

Phase 2 Recruiting
62 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡